During the last decade there has been an evolution in the treatment of resistant/refractory thyroid cancer, by inducing targeted therapies (anti-VEGF, anti-RET, anti-PDGF etc.), the so-called Multiple Kinase Inhibitors (MKI’s). Here, RET is linked to thyroid cancer.